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Abstract: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative
disease of the central nervous system. Neurological deficits are attributed to inflammatory
demyelination, which compromises axonal function and survival. These are mitigated in experimental
models by rapid and often complete remyelination of affected axons, but in MS this endogenous
repair mechanism frequently fails, leaving axons increasingly vulnerable to the detrimental effects
of inflammatory and metabolic stress. Understanding the molecular basis of remyelination and
remyelination failure is essential to develop improved therapies for this devastating disease. However,
recent studies suggest that this is not due to a single dominant mechanism, but rather represents
the biological outcome of multiple changes in the lesion microenvironment that combine to disrupt
oligodendrocyte differentiation. This identifies a pressing need to develop technical platforms to
investigate combinatory and/or synergistic effects of factors differentially expressed in MS lesions
on oligodendrocyte proliferation and differentiation. Here we describe protocols using primary
oligodendrocyte cultures from Bl6 mice on 384-well nanofiber plates to model changes affecting
oligodendrogenesis and differentiation in the complex signaling environment associated with
multiple sclerosis lesions. Using platelet-derived growth factor (PDGF–AA), fibroblast growth
factor 2 (FGF2), bone morphogenetic protein 2 (BMP2) and bone morphogenetic protein 4 (BMP4)
as representative targets, we demonstrate that we can assess their combinatory effects across a
wide range of concentrations in a single experiment. This in vitro model is ideal for assessing the
combinatory effects of changes in availability of multiple factors, thus more closely modelling the
situation in vivo and furthering high-throughput screening possibilities.
Keywords: oligodendrocyte; myelin; remyelination; screening; nanofibers; multiple sclerosis
1. Introduction
Multiple Sclerosis (MS) is a chronic inflammatory, demyelinating disease of the central nervous
system (CNS) with diverse clinical presentations and a heterogeneous histopathology. It is suggested
that demyelination and failure of remyelination lead to axonal degeneration and functional impairment.
This axonal pathology is the underlying cause of disability in patients with MS and is attributed to
the detrimental effects of inflammatory demyelination on the functional and structural integrity of
affected axons [1,2]. In this context, demyelination not only disrupts axonal conduction per se but also
disrupts metabolic support provided via the myelin sheath whilst simultaneously enhancing axonal
susceptibility to damage by inflammatory mediators, a combination of effects predicted to exacerbate
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axonal loss and result in irreversible neurological deficits. These effects of demyelination on axonal
health are mitigated in animal models by rapid and often complete remyelination by oligodendrocytes
derived from an endogenous pool of oligodendrocyte progenitor cells (OPCs). However, in MS, this
repair mechanism frequently fails, leaving affected axons increasingly vulnerable to inflammatory and
metabolic stress [3].
Why remyelination fails in MS remains poorly understood, but it is attributed to changes in the
lesion microenvironment that compromise OPC recruitment, survival and/or differentiation, and axon
function [4–9], which are compounded by factors including disease chronicity [10] and factors not
related to the disease, such as gender and age [11].
Developmental myelination is under tight spatial and temporal control and is coordinated by
factors including neuronal activity, changes affecting growth factor availability, and stage specific
expression of their receptors within the oligodendrocyte lineage. It is assumed that remyelination
recapitulates many features of this complex developmental program [12]. It is therefore not surprising
that remyelination can be disrupted experimentally by many different mechanisms, including
inappropriate re-expression of developmental cues and continuing presence of myelin debris as
well as changes affecting growth factor availability, progenitor cell migration, and composition of the
extracellular matrix [13]. Strong circumstantial arguments can be made for each of these mechanisms
contributing to remyelination failure in MS, but their relative importance is unclear. To resolve this
question, several groups performed comparative transcriptomic studies on normal-appearing white
matter, active inflammatory demyelinating lesions, remyelinating lesions, and inactive chronically
demyelinated lesions with the aim of identifying specific molecules or signaling pathways that may
provide targets for treatment strategies designed to enhance remyelination [14–17]. However, these
studies have failed to identify any single factor or pathway consistently associated with remyelination
failure. Instead they demonstrate there is significant intra-study and -lesion heterogeneity with regard
to the expression of genes predicted to influence oligodendrogenesis and myelination between different
lesion types. An observation that has led us to speculate failure of remyelination is the net result of
dysregulation of multiple pathways.
To understand the consequences of this heterogeneity, an experimental platform is required in
which we can rapidly assess concentration dependent effects of multiple factors on OPC proliferation,
differentiation, and myelination. Primary co-culture systems are suitable to investigate specific
questions on oligodendrocyte development and myelination, but due to the complexity of these
systems, direct effects on proliferation, differentiation, and myelination can hardly be discerned from
indirect effects. Quantitative approaches are often handicapped due to the cell heterogeneity in these
co-culture systems. In 2012, the research group of Jonah Chan demonstrated oligodendrocytes are
capable of myelinating engineered nanofibers [18]. This technique has enormous potential to evaluate
the effect of single molecules on oligodendrocyte myelination, and to identify potential therapeutic
targets [19].
To demonstrate the effectiveness of this platform we focused on four factors differentially regulated
in MS lesions that influence OPC proliferation, differentiation, and myelination: platelet-derived
growth factor subunit A dimer (PDGF–AA [20]), fibroblast growth factor 2 (FGF2 [15,21]), bone
morphogenetic protein 2 (BMP2 [22]), and bone morphogenetic protein 4 (BMP4 [22,23]). We were
able to show that our model system is an efficient way of screening effects in a multifactor treatment
paradigm. A major application of this model system may be the modeling of the complex environment
in a demyelinated lesion.
2. Materials and Methods
2.1. Oligodendrocyte Cell Culture
Primary oligodendrocyte cultures were prepared from post-natal day 0–2 C57Bl/6 mice, as
described before [24]. Briefly, forebrains were collected aseptically and after removal of the meninges,
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the cortices were triturated 35 times through a 1 mL pipet in “DBGFP”medium (Table 1) and filtered
through a 70 µm cell strainer. Cells were grown in suspension culture in DBGFP at 37 ◦C, 5%
CO2, and 95% air in DBGFP to generate oligospheres. After two weeks, cultures from multiple
donors were pooled, centrifuged at 300× g for five minutes, and resuspended in plating medium
(Table 1). After gentle trituration through a G27 needle, cells were plated at a density of 10,000
oligodendrocytes/well in 384-well nanofiber plates (Z694568–1EA, Sigma–Aldrich Chemie GmbH,
Buchs, Switzerland) coated with poly–l–lysine (P4707–50ML, Sigma–Aldrich Chemie GmbH, Buchs,
Switzerland).
Table 1. Composition of used cell culture media.
Product Product Number Company Dilution/Concentration
DBGFP: Dulbecco’s Modified Eagle’s Medium/Nutrient






B–27 Supplement (50×) 17504001 Gibco/ThermoFisher
Scientific, USA
1:50
l–Glutamine (200 mM) 25030024 ThermoFisher Scientific,
USA
1:100
Fibroblast growth factor 2 (FGF2) 100–18B PeproTech EC, Ltd., UK 20 ng/mL




Plating: DBGFP medium without PDGF–AA and FGF2.
Treatment: DBGFP medium without PDGF–AA and FGF2 and one/two/three of the following:
PDGF–AA 100–13A PeproTech EC, Ltd., UK 0–20 ng/mL
FGF2 100–18B PeproTech EC, Ltd., UK 0–20 ng/mL
Bone morphogenetic protein 2 (BMP2) 120–02 PeproTech EC, Ltd., UK 0–100 ng/mL
BMP4 315–27 PeproTech EC, Ltd., UK 0–100 ng/mL
2.2. Immune Fluorescence Stainings
Immunofluorescent stainings were either performed with 4′,6-diamidin-2-phenylindol (DAPI)
and against galactosylceramide (O1), platelet-derived growth factor alpha (PDGFRa) and myelin basic
protein (MBP) or with DAPI and against myelin oligodendrocyte glycoprotein (MOG), oligodendrocyte
lineage factor 2 (OLIG2), and glial fibrillary acidic protein (GFAP) (Table 2).
Table 2. Dyes and antibodies used for the stainings.
Dye/Antibody Type/Species Company Cat. Nr. Dilution
4′,6-Diamidin-2-phenylindol (DAPI) - Sigma Aldrich 1:15,000
O1 Monoclonal/Mouse Kindly provided by Prof. M. Schwab, Zürich, CH D9542-10 mg 1:250
Platelet derived growth factor alpha (PDGFRa) Polyclonal/Rabbit Kindly provided by Prof. William B. Stallcup, LaJolla, CA, US 1:4000
Myelin basic protein (MBP) Monoclonal/Rat Merck Millipore 1:250
Myelin oligodendrocyte glycoprotein (MOG) Monoclonal/Mouse Kindly provided by Prof. R. Reynolds, London, UK MAB386 1:250
Oligodendrocyte linear factor 2 (OLIG2) Polyclonal/Rabbit Merck Millipore Clone Z12 1:2000
Glial fibrillary acidic protein (GFAP) Polyclonal/Chicken Aves Labs AB9610 1:2000
dk–a–m–488 Monoclonal/Donkey Jackson ImmunoResearch AB_2313547 1:700
dk–a–rb–594 Monoclonal/Donkey Jackson ImmunoResearch 1:700
dk–a–rt–647 Monoclonal/Donkey Jackson ImmunoResearch 715-545-140 1:700




First, for staining of living cells (O1 staining), the cultured cells were blocked in 10% fetal bovine
serum in DMEM/F12 medium at 37 ◦C for 30 min, and thereafter the cells were incubated for 30 min
with O1 supernatant at room temperature. All wells were then washed twice with phosphate buffered
saline (PBS), and fixed with 4% paraformaldehyde for 15 min at room temperature. Thereafter, the
cells were washed three times with PBS for five minutes and incubated for 1 h with blocking solution
(5% bovine serum albumin, 1% normal donkey serum, 0.2% Triton-X100 in PBS). Primary antibodies
were diluted in blocking solution and applied overnight at 4 ◦C (Table 2). The cells were washed three
times with PBS (15 min each at room temperature). The secondary antibody (Table 2) was then applied
for one hour in PBS with DAPI at room temperature. The cells were washed three times with PBS
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again and then rinsed twice with tap water and covered with ibidi mounting medium (ibidi GmbH,
Gräfelfing, Germany, Cat. No. 50001).
2.3. Image Analysis
384-well plates were imaged using a Nikon Ti2 microscope (Nikon, Tokyo, Japan) fitted with a
Prime 95B camera (Teledyne Photometrics, Tucson, AZ, USA). The center of each well was scanned
(6 × 6 fields of view) with z-stacks over 27.2 µm with 1.7 µm per slice and a resolution of 0.28 micrometer
per pixel. This resulted in images of 2.37 × 2.37 mm or about 51% of the total well area. For the
illustrative images of Figure 1, an Olympus IX83 microscope was used. All image analysis was then
performed with ImageJ (Version 1.51s, FIJI distribution, NIH, Bethesda, MD, USA). Stacks were first
compressed to single images with Z-Project by maximum intensity. For quality control, every DAPI
image was reviewed for proper focusing and wells were rescanned if more than 5% of the image was out
of focus. All images were then converted to 8-bit images and thresholded at values of 125/255 (DAPI),
160/255 (PDGFRa) or 75/255 (MBP). The percentage of pixels above the threshold was considered as the
percent of area positive for the respective marker and used for further analysis.
2.4. Statistical Analysis
All statistical analysis was performed using R (R Development Core Team, Vienna, Austria,
2010). The experiments were performed on three 384-well plates, leading to a total of six wells per
treatment condition for DAPI and three wells per treatment condition for all other stainings (Figure 1B).
Each plate was normalized to the average measurement per plate, the measurements and treatments
were log-transformed, and a pseudo count was added to the treatment values to avoid log of zero.
Obvious outliers were removed from the analysis and data from all three plates was pooled for the
analysis. Two different linear models were fitted: one with PDGF–AA, FGF2, and BMP2 and all
possible interaction terms as independent variables and the other with BMP4 instead of BMP2. p-values
smaller than 0.01 were considered to be statistically significant.
2.5. Data Availability
All original greyscale microscopy images used for image analysis are deposited on the BioStudies
database of the European Bioinformatics Institute (EMBL-EBI, Hinxton, Cambridge, UK, accession
number S-BIAD10, link: https://www.ebi.ac.uk/biostudies/BioImages/studies/S-BIAD10). All original
image analysis data may be found in the supplements (Supplementary Data 1).
3. Results
3.1. The Nanofiber Cell Cultures Give Rise to Highly Pure Proliferating and Differentiating Oligodendrocytes
Primary mouse oligodendrocytes were cultivated as spheres and plated on three 384-well nanofiber
plates for 14 days with PDGF–AA and FGF2 in combination or independently concentrated at 0, 0.625,
1.25, 2.5, 5, 10, or 20 ng/mL and BMP2 or BMP4 concentrated at 0, 10, 50, or 100 ng/mL (Figure 1a,b).
The cells were then stained for PDGFRa, O1, MBP, OLIG2, MOG, or GFAP and scanned with a
microscope. A total of 911 of 912 wells were correctly focused and could be used for further analysis.
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Figure 1. Experimental set up and cell culture characterization. (a) Illustration of the experimental 
timeline showing the sacrifice of the mice, two-week growth of the oligospheres, and plating on the 
nanofibers. (b) Schematic drawing of the experimental set-up of the 384-nanofiber plates. (c)-(l) 
Representative images of the different stainings. (c) The cells proliferated in clusters growing along 
the nanofibers. (d) Most of the nuclei (stained with DAPI) colocalized with the oligodendrocyte 
lineage marker OLIG2 (arrows, well treated with 20ng/mL platelet-derived growth factor subunit A 
dimer (PDGF–AA) and fibroblast growth factor 2 (FGF2). (e) Note, some nuclei showed a dense and 
sometimes fragmented morphology and were not positive for oligodendrocyte lineage factor 2 
(OLIG2) (arrowheads, (d and e)). This was more pronounced in the wells with less PDGF–AA and 
FGF2 and more bone morphogenetic protein 2 (BMP2) (well treated with 0.625ng/mL PDGF–AA and 
FGF2). (f) Dense cell clusters were not eligible for accurate counting of the nuclei. (g, h, and k) 
PDGFRa and MBP were mainly expressed within the clusters, while (i and j) the larger MOG 
positive cells were usually situated in proximity but not within the clusters. (l) Possible 
contamination with glial fibrillary acidic protein (GFAP) positive astrocytes was very rare, with most 
wells showing no staining for GFAP. 
Figure 1. Experimental set up and cell culture characterization. (a) Illustration of the experimental
timeline showing the sacrifice of the mice, two-week growth of the oligospheres, and plating on
the nanofibers. (b) Schematic drawing of the experimental set-up of the 384-nanofiber plates.
(c–l) Representative images of the different stainings. (c) The cells proliferated in clusters growing
along the nanofibers. (d) Most of the nuclei (stained with DAPI) colocalized with the oligodendrocyte
lineage marker OLIG2 (arrows, well treated with 20 ng/mL platelet-derived growth factor subunit A
dimer (PDGF–AA) and fibroblast growth factor 2 (FGF2). (e) Note, some nuclei showed a dense and
sometimes fragmented morphology and were not positive for oligodendrocyte lineage factor 2 (OLIG2)
(arrowheads, (d and e)). This was more pronounced in the wells with less PDGF–AA and FGF2 and
more bone morphogenetic protein 2 (BMP2) (well treated with 0.625 ng/mL PDGF–AA and FGF2).
(f) Dense cell clusters were not eligible for accurate counting of the nuclei. (g, h, and k) PDGFRa and
MBP were mainly expressed within the clusters, while (i and j) the larger MOG positive cells were
usually situated in proximity but not within the clusters. (l) Possible contamination with glial fibrillary
acidic protein (GFAP) positive astrocytes was very rare, with most wells showing no staining for GFAP.
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Image inspection revealed clusters of cells oriented along the nanofibers expressing the
oligodendrocyte lineage marker OLIG2 (Figure 1c, arrows). Some nuclei did not show colocalization
with OLIG2, these nuclei were however most often dense or fragmented, suggestive of cell death
(Figure 1d, arrowheads). This phenomenon was more pronounced in the wells treated without or with
only relatively low concentrations of PDGF–AA and FGF2 (Figure 1e). Initial efforts to quantify the
number of cells by counting the DAPI nuclei demonstrated cell numbers between 3000 (e.g., upon
100 ng/mL BMP2 treatment) and 12,000 cells (e.g., upon 20 ng/mL PDGF-AA and FGF2 treatment) per
imaged area to be present, clearly indicating that proliferation and cell death occurred after plating of
the initial 10,000 cells per well. However, in particular, the dense cell clusters were not eligible for
automated cell counting, and thus a more simplified approach of evaluating the area stained for DAPI
was chosen as a surrogate marker for the number of cells present (Figure 1f).
PDGFRa was mostly expressed in the densely populated areas, with only little expression between
the clusters (Figure 1c). Expression of the myelin protein MOG was most often detected at the border
of the dense cell clusters (Figure 1c), whereas MBP signal was both detected in smaller cells within the
clusters and in larger cells between the clusters (Figure 1c). Staining for astrocytes with GFAP revealed
only very few astrocytes being present, while most wells showed no GFAP-positive cell (Figure 1c).
3.2. Cell Density Is Strongly Increased by Platelet-Derived Growth Factor Subunit A Dimer (PDGF–AA),
While Fibroblast Growth Factor 2 (FGF2) Potentiated the Effect of PDGF–AA and Bone Morphogenetic Protein
2 (BMP2) Overrides the Effects of PDGF–AA
After 14 days in culture, the OPCs have proliferated to cover on average 1.7% of the area with DAPI
(range: 0.5–19.3%). We detected a gradient of increased cell density with rising levels of PDGF–AA as
detected by the area stained positive for DAPI, independent of the FGF2 concentration (Figure 2a,b).
FGF2 in absence of PDGF–AA did not show an effect on cell density, but enhanced cell density with
increasing concentrations if a certain amount of PDGF–AA was simultaneously present (Figure 2a,b).
The effect of PDGF–AA on cell density and the interaction with FGF2 was statistically significant
(Table 3).












platelet-derived growth factor subunit
A dimer (PDGF–AA) 0.26 <10
−8 0.49 <10−13
Fibroblast growth factor 2 (FGF2) ns ns
PDGF–AA:FGF2 0.19 <10−15 0.11 <10−5
Bone morphogenetic protein 2 (BMP2) 0.11 <10−5 ns
PDGF–AA:BMP2 −0.05 <10−7 −0.08 <10−6
FGF2:BMP2 ns ns







PDGF–AA 0.21 <10−5 0.41 <10−8
FGF2 ns ns





The colon “:” depicts interaction terms between the factors, ns: not significant.
Cells 2019, 8, 1422 7 of 13
Cells 2019, 8, x 7 of 14 
 
3.2. Cell Density Is Strongly Increased by Platelet-Derived Growth Factor Subunit A Dimer (PDGF–AA), 
While Fibroblast Growth Factor 2 (FGF2) Potentiated the Effect of PDGF–AA and Bone Morphogenetic 
Protein 2 (BMP2) Overrides the Effects of PDGF–AA 
After 14 days in culture, the OPCs have proliferated to cover on average 1.7% of the area with 
DAPI (range: 0.5–19.3%). We detected a gradient of increased cell density with rising levels of 
PDGF–AA as detected by the area stained positive for DAPI, independent of the FGF2 concentration 
(Figure 2a,b). FGF2 in absence of PDGF–AA did not show an effect on cell density, but enhanced cell 
density with increasing concentrations if a certain amount of PDGF–AA was simultaneously present 
(Figure 2a,b). The effect of PDGF–AA on cell density and the interaction with FGF2 was statistically 
significant (Table 3). 
Already, relatively low concentrations of 10ng/mL of BMP2 over 14 days were able to nullify 
the cell density effect of PDGF–AA and FGF2, with higher concentrations of BMP2 showing no 
additional effect. BMP2 showed no effect if PDGF–AA was not present, and the calculated positive 
main effect of BMP2 from the linear model should not be interpreted due to the detected interactions 
with PDGF–AA and FGF2 (Figure 2c,d, Table 3). BMP4 showed no effect on cell density for all 
concentrations tested (Figure 2e,f, Table 3). 
 
Figure 2. Oligodendrocyte progenitor cells (OPC) cell density after 14 days of multifactor treatment. 
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dependent on the platelet-derived growth factor subunit A dimer (PDGF–AA) and fibroblast growth 
factor 2 (FGF2) treatment. (b) Representative microscopy images showing the DAPI signal upon 
different PDGF–AA and FGF2 treatments. (c) Heatmap showing the percent of area positive for 
DAPI dependent on the PDGF–AA/FGF2 and bone morphogenetic protein 2 (BMP2) treatment. (d) 
Representative microscopy images of PDGF–AA and FGF2 concentrated at 20ng/mL and with BMP2 
levels of 0–100 ng/mL. (e) Heatmap showing the percent of area positive for DAPI dependent on the 
PDGF–AA/FGF2 and BMP4 treatment. (f) Representative microscopy images of PDGF–AA and FGF2 
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Figure 2. Oligodendrocyte progenitor cells (OPC) cell density after 14 days of multifactor treatment.
(a) Heatmap showing the percent of area positive for DAPI, as a measure for OPC cell density, dependent
on the platelet-derived growth factor subunit A dimer (PDGF–AA) and fibroblast growth factor 2 (FGF2)
treatment. (b) Representative microscopy images showing the DAPI signal upon different PDGF–AA
and FGF2 treatments. (c) Heatmap showing the percent of area positive for DAPI dependent on the
PDGF–AA/FGF2 and bone morphogenetic protein 2 (BMP2) treatment. (d) Representative microscopy
images of PDGF–AA and FGF2 concentrated at 20 ng/mL and with BMP2 levels of 0–100 ng/mL. (e)
Heatmap showing the percent of area positive for DAPI dependent on the PDGF–AA/FGF2 and BMP4
treatment. (f) Representative microscopy images of PDGF–AA and FGF2 concentrated at 20 ng/mL and
with BMP4 levels of 0–100 ng/mL.
Already, relatively low concentrations of 10 ng/mL of BMP2 over 14 days were able to nullify the
cell density effect of PDGF–AA and FGF2, with higher concentrations of BMP2 showing no additional
effect. BMP2 showed no effect if PDGF–AA was not present, and the calculated positive main effect of
BMP2 from the linear model should not be interpreted due to the detected interactions with PDGF–AA
and FGF2 (Figure 2c,d, Table 3). BMP4 showed no effect on cell density for all concentrations tested
(Figure 2e,f, Table 3).
3.3. Early Differentiation Is Promoted by Platelet-Derived Growth Factor Subunit A Dimer (PDGF–AA),
Enhanced by Fibroblast Growth Factor 2 (FGF2) and Inhibited by Bone Morphogenetic Protein 2 (BMP2)
14 days after seeding the cells have differentiated to cover an average of about 43.3% with PDGFRa
signal (range: 28.4–77.8%). A gradient of PDGFRa expression is detected with increasing levels of
PDGF–AA independent of the FGF2 concentration (Figure 3a,b). With increasing levels of FGF2, a
gradient of PDGFRa signal is only detected if minimal concentrations of PDGF–AA are present. Both
the effect of PDGF–AA and the interaction of PDGF–AA and FGF2 reached statistical significance
(Table 3).
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images of PDGF–AA and FGF2 concentrated at 20 ng/mL and with BMP2 levels of 0–100 ng/mL. (e) 
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3.4. Late Differentiation is Unaffected by Platelet-Derived Growth Factor Subunit A Dimer (PDGF–AA), 
Fibroblast Growth Factor 2 (FGF2), Bone Morphogenetic Protein 2 (BMP2) and BMP4 
The treatments with PDGF–AA, FGF2, BMP2, and BMP4 did not demonstrate statistically 
significant effects on MBP expression (Figure 4a–e, Table 3). Though BMP2 seemed to inhibit late 
differentiation with high concentrations, this effect was not linear and did not reach statistical 
significance (Figure 4c,d). Upon visual investigation, we observed no apparent change in the length, 
processes, or area of the MBP expressing cells. 
Figure 3. Early oligodendrocyte progenitor cells (OPC) differentiation after 14 days of multifactor
treatment. (a) Heatmap showing the percent of area positive for platelet-derived growth factor alpha
(PDGFRa), as a easure for early OPC differentiation, dependent on the platelet-derived growth factor
subunit A dimer (PDGF–AA) and fibroblast growth factor 2 (FGF2) treatment. (b) Representative
microscopy images showing the PDGFRa expression upon different PDGF–AA and FGF2 treatments.
(c) Heatmap showing the PDGFRa expression in dependency of the PDGF–AA/FGF2 and bone
morphogenetic protein 2 (BMP2) treatment. (d) Representative microscopy images of PDGF–AA and
FGF2 concentrated at 20 ng/mL and with BMP2 levels of 0–100 ng/mL. (e) Heatmap showing the
PDGFRa expression in dependency of the PDGF–AA/FGF2 and BMP4 treatment. (f) Representative
microscopy images of PDGF and FGF2 concentrated at 20 ng/mL and with BMP4 levels of 0–100 ng/mL.
This gradient disappears with increasing levels of BMP2 dose dependent between 0–50 ng/mL
with only minimal additional effect of 100 ng/mL BMP2 (Figure 3c,d). While the main effect of BMP2 did
not reach significance, the interaction of BMP2 with PDGF–AA and with PDGF–AA and FGF2 reached
statistical significance (Table 3). BMP4 did not show any effect on PDGFRa expression, independent of
its concentration (Figure 3e,f, Table 3).
3.4. Late Differentiation is Unaffected by Platelet-D rived Growth Factor Subunit A Dimer (PDGF–AA),
Fibroblast Growth Factor 2 (FGF2), Bone Morphogenetic Protein 2 (BMP2) and BMP4
The treatments with PDGF–AA, FGF2, BMP2, and BMP4 did not demonstrate statistically
significant effects on MBP expression (Figure 4a–e, Table 3). Though BMP2 seemed to inhibit
late differentiation with high concentrations, this effect was not linear and did not reach statistical
significance (Figure 4c,d). Upon visual investigation, we observed no apparent change in the length,
processes, or area of the MBP expressing cells.
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and with BMP2 levels of 0–100 ng/mL. (e) Heatmap showing the influence of BMP4 on MBP 
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Figure 4. Late oligodendrocyte progenitor cells (OPC) differentiation after 14 days of ultifactor
treatment. (a) Heatmap showing the influence of platelet-derived growth factor subunit A dimer
(PDGF–AA) and fibroblast growth factor 2 (FGF2) on late differentiation measured as percent of area
positive for myelin basic protein (MBP). (b). Representative microscopy images showing the MBP
expression. (c) Heatmap showing the influence of bone morphogenetic protein 2 (BMP2) on MBP
expression. (d) Representative microscopy images of PDGF–AA and FGF2 concentrated at 20 ng/mL
and with BMP2 levels of 0–100 ng/mL. (e) Heatmap showing the influence of BMP4 on MBP expression.
(f) Representative microscopy images of PDGF–AA and FGF2 concentrated at 20 ng/mL and with
BMP4 levels of 0–100 ng/mL.
4. Discussion
Recently, high-throughput screening studies have identified several compounds that promote
remyelination [25–28], including clemastine, which is currently being investigated in a phase II clinical
trial in optic neuritis (Clinical trials identifier NCT02521311). However, these screens focused on
screening individual factors under culture conditions that do not replicate the complex pathologic
environment of an MS lesion. To address this question, we elected to build on existing technologies to
develop a platform in which we could rapidly screen for multiparametric effects that mimic the lesion
microenvironment and its effects on cells of the oligodendrocyte lineage.
We successfully established a cell culture system in which highly purified oligodendrocytes
myelinate nanofibers in 384-well nanofiber plates to reliably and efficiently quantify the effects
of multi-factor treatments on oligodendrocyte development and myelination. We implemented a
standardized operating procedure for cell culturing, imaging, and image analysis that optimizes
reproducibility and mapped combinatory, concentration-dependent effects of PDGF–AA, FGF2, BMP2
and BMP4 on oligodendrocytes and myelination.
PDGF–AA is known to be essential for oligodendrocyte generation and survival [29] and
differentiation [30]. We detected a positive effect of PDGF–AA on the number of cells as reported
before [31–33]. We also detected a positive effect of PDGF–AA on early OPC differentiation into
PDGFRa positive cells. This simultaneous positive effect on differentiation is controversial, however, as
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a factor promoting proliferation effectively keeps a cell in the cell-cycle, while promoting differentiation
requires the cell to exit the cell-cycle. Cell culture experiments have demonstrated that proliferation
may cause mechanical restraint, which then induces OPC differentiation indirectly [34]. We interpret
the expression of PDGFRa mainly within the more densely populated clusters in this manner. In our
cell culture system, FGF2 showed no effect on cell density and early OPC differentiation in absence of
PDGF–AA. However, FGF2 showed an increasing effect on both cell density and differentiation with
rising levels of PDGF–AA being present, thus enhancing the effect of PDGF–AA. As suggested by
our own observations, FGF2 has been shown to not be essential for OPC development, in contrast to
PDGF–AA [30]. FGF2 is further known to stimulate OPC proliferation and migration and to increase
oligodendrocyte process elongation [35,36], but also to have a negative effect on differentiation [30]
and myelination [37], by keeping the OPC in the cell-cycle.
BMPs were reported to inhibit OPC proliferation, oligodendrocyte maturation, and myelin protein
expression and to push OPCs into the astrocyte lineage, if thyroid hormone is present as well [38–41].
In line with these previous data, our results demonstrate a strong reduction of OPC cell density and
differentiation caused by BMP2. We further demonstrated that BMP2 effectively overwrites the effect
of PDGF–AA and FGF2 already at low concentrations, irrespective of the concentrations of PDGF–AA
and FGF2. As only very few GFAP expressing cells developed within our culture systems, we did not
expect and did not detect an increase in astrocytes when adding BMP2. In our study, BMP4 had no
effect on cell density and differentiation. This may be explained by the fact that BMP4 only acts in a
certain time frame of OPC development, mainly during the GalC positive phase. In our culture system,
this phase may have already been passed during the two weeks the cells were kept as oligospheres
prior to seeding on the nanofibers.
As our system was intended to model the signaling environment of a demyelinated lesion by
expressing factors known to be expressed there, we did not expect to detect many cells showing
late differentiation. Accordingly, we detected few MBP positive cells, statistically irrespective of the
treatment. This may be suggestive of a fate determination prior to treatment beginning, possibly
already within the brain or during the oligosphere stage. These cells differentiated remarkably despite
high BMP2 levels, which otherwise efficiently inhibit both proliferation and early differentiation. Our
treatments however are not optimized for assessing late differentiation and myelination, as this would
require for example a withdrawal of PDGF–AA and FGF2, which keep the OPCs within proliferation.
Even though the dysregulation of the factors tested here has been demonstrated on RNA and
protein level in MS lesions, there is currently no data available concerning the local concentrations
of these factors. While the concentrations of PDGF–AA and FGF2 have been measured in the
cerebrospinal fluid [42–44], BMP levels have so far only been determined within blood serum samples
of MS patients [45]. However, this data cannot easily be extrapolated to the local situation within
lesions, where concentrations could potentially reach much higher levels.
We may conclude that our cell culture system is suitable for studying more complex effects of
multifactor treatments on oligodendrocytes. This approach enables to better model the signaling
environment of MS lesions, where the decision is made, whether lesions are chronically demyelinated
or remyelination and thus functional recovery may occur. To this end, any improved mapping and
quantification of the factors present in vivo in MS lesions may improve the in vitro model system. This
model may then serve as an alternative platform to screen novel therapeutic approaches in the ongoing
research on remyelination therapy.
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